# Elevance Health, Inc. (ELV) Stock Report: Analyzing Growth Potential with a 9.87% Upside

- Link: https://www.directorstalkinterviews.com/elevance-health-inc-elv-stock-report-analyzing-growth-potential-with-a-9-87-upside/4121233330
- Published: 2026-01-05T11:22:33+00:00
- Author: Madison Wilson

Investors eyeing the healthcare sector should take a closer look at Elevance Health,
Inc. (NYSE: ELV), a prominent player in the healthcare plans industry. With a substantial
market capitalization of $79.77 billion, Elevance Health, formerly known as Anthem,
Inc., has positioned itself as a formidable force in delivering a wide range of 
health-related services across the United States. The company’s recent rebranding
to Elevance Health underscores its commitment to transforming and elevating healthcare
experiences.

At a current trading price of $354.25, Elevance Health sits within a 52-week range
of $274.66 to $452.69. This stock has recently witnessed a minor price change of
0.01%, reflecting the market’s stable sentiment towards it. However, the real intrigue
for investors lies in its potential upside of 9.87%, based on the average target
price of $389.21 set by analysts.

Elevance Health’s strategic focus on diversified healthcare services, including 
health benefits, pharmacy services, and specialty care, has propelled its revenue
growth to an impressive 12.30%. Despite the absence of specific valuation metrics
like P/E and PEG ratios, the company’s forward P/E ratio of 13.19 suggests a reasonable
valuation relative to its earnings outlook. Additionally, with an EPS of $24.55,
the company demonstrates strong profitability, further supported by a return on 
equity of 12.57%.

Investors will find comfort in Elevance Health’s robust free cash flow, totaling
over $5.1 billion, which underscores its financial health and ability to reinvest
in growth opportunities. The company’s dividend yield of 1.93% with a payout ratio
of 27.55% offers a stable income stream, making it an attractive option for dividend-
focused investors.

Analyst sentiment towards Elevance Health is predominantly positive, with 13 buy
ratings and 8 hold ratings, and no sell recommendations. This consensus reflects
confidence in the company’s strategic positioning and growth prospects. The target
price range of $320.00 to $507.00 highlights diverse opinions but underscores the
stock’s potential for appreciation.

Technical indicators provide further insights into Elevance Health’s market dynamics.
The stock’s 50-day moving average of $334.50 and a 200-day moving average of $353.48
suggest a bullish trend, with the RSI (14) at 69.85 indicating that the stock is
nearing overbought territory. The MACD value of 4.55, above the signal line of 4.41,
supports the possibility of continued upward momentum.

Elevance Health’s extensive portfolio, including offerings under notable brands 
such as Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon, positions it 
well to capitalize on the growing demand for integrated healthcare solutions. Its
comprehensive services span health benefits, pharmacy services, specialty care, 
and innovative healthcare technologies, empowering it to deliver value across the
healthcare continuum.

Headquartered in Indianapolis, Indiana, Elevance Health continues to leverage its
operational scale and expertise to navigate the complexities of the healthcare landscape.
Investors seeking exposure to a dynamic and evolving sector should consider Elevance
Health as a compelling addition to their portfolios, given its growth potential 
and strategic initiatives aimed at enhancing healthcare delivery.

Share on:
